Rosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group research. Ann Oncol. 2004;15(8):1173. Fleming GF, Brunetto VL, Cella D, Appear KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or with no paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):21596. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression with the epidermal development component receptor and its ligand transforming development aspect alpha is regular in resectable non-small cell lung cancer but won’t predict tumor progression. Clin Cancer Res. 1997;3(four):5152. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth aspect receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res. 2001;7(7):1850. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth component receptor, transforming development component alpha, and epidermal growth component and their expression in human gliomas in vivo. Cancer Res. 1991;51(eight):21642. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):18332. Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, et al. Significance of urinary epidermal development factor and its receptor expression in human bladder cancer. Anticancer Res. 1997;17(2B):1293. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, et al. The correlation concerning cytoplasmic overexpression of epidermal development component receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.4,5-Dicyanoimidazole web Pancreas.Biotin alkyne MedChemExpress 2004;29(one):e1.PMID:24257686 King CR, Kraus MH, Aaronson SA. Amplification of the novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974. Grandis JR, Sok JC. Signaling through the epidermal growth element receptor through the growth of malignancy. Pharmacol Ther. 2004;102(1):376. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53(1):842. Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Distefano M, D’Andrea G, et al. Significance of epidermal development component receptor expression in main human endometrial cancer. Int J Cancer. 1994;56(1):260. Niikura H, Sasano H, Matsunaga G, Watanabe K, Ito K, Sato S, et al. Prognostic value of epidermal growth element receptor expression in endometrioid endometrial carcinoma. Hum Pathol. 1995;26(8):892. Thoury A, Descatoire V, Kotelevets L, Kannengiesser C, Bertrand G, Theou-Anton N, et al. Proof for distinctive expression profiles for c-Met, EGFR, PTEN as well as the mTOR pathway in low and substantial grade endometrial carcinomas in a cohort of consecutive gals. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Histol Histopathol. 2014;29(eleven):14556. Ejskjaer K, Sorensen BS, Poulsen SS, Forman A, Nexo E, Mogensen O. Expression of the epidermal development component technique in endometrioid endometrial cancer. Gynecol Oncol. 2007;104(one):1587. Mori N, Kyo S, Nakamura M, Hashimoto M, Maida Y, Mizumoto Y, et al. Expression of HER-2 affects patient survival and.